Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Apellis Pharmaceuticals Inc (APLS)  
$26.69 0.67 (2.43%) as of 4:30 Tue 8/19


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 132,769,000
Market Cap: 3.54(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $16.36 - $41.05
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapeutic compounds to treat disease through the inhibition of the complement system at the level of C3. Co.'s primary product candidate, pegcetacoplan, is a conjugate of a compstatin analogue, formulated both for intravitreal administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin. Co. is also developing APL-9 for the prevention of complement immune system activation coincident with adeno-associated virus vector administration for gene therapies and other indications.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 169,090 174,842 310,269 1,231,609
Total Sell Value $3,403,426 $3,547,758 $7,857,654 $60,821,949
Total People Sold 2 3 12 14
Total Sell Transactions 5 7 53 127
End Date 2025-05-22 2025-02-18 2024-08-20 2023-08-21

   
Records found: 804
  Page 1 of 33  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Watson David O. General Counsel   •       •      –    2025-08-18 4 AS $27.80 $139,000 D/D (5,000) 123,730     -
   Francois Cedric Chief Executive Officer   •       •      –    2025-07-17 4 AS $20.21 $398,735 D/D (19,725) 331,605 38%     
   Francois Cedric Chief Executive Officer   •       •      –    2025-07-17 4 OE $4.31 $38,777 D/D 8,997 351,330     -
   Watson David O. General Counsel   •       •      –    2025-07-16 4 AS $19.55 $97,750 D/D (5,000) 128,730 41%     
   Francois Cedric Chief Executive Officer   •       •      –    2025-07-15 4 AS $20.09 $38,168 D/D (1,900) 342,333 43%     
   Francois Cedric Chief Executive Officer   •       •      –    2025-07-15 4 OE $4.31 $3,448 D/D 800 344,233     -
   Francois Cedric Chief Executive Officer   •       •      –    2025-07-14 4 AS $20.19 $2,774,923 D/D (137,465) 343,433 39%     
   Francois Cedric Chief Executive Officer   •       •      –    2025-07-14 4 OE $4.31 $281,025 D/D 65,203 480,898     -
   Chopas James George VP/Chief Accounting Officer   •       •      –    2025-06-18 4 A $0.00 $0 D/D 6,250 54,205     -
   Watson David O. General Counsel   •       •      –    2025-06-16 4 AS $18.77 $93,850 D/D (5,000) 133,730 52%     
   Boucher Kelley Chief People Officer   •       •      –    2025-06-09 4 A $0.00 $0 D/D 45,095 67,182     -
   Boucher Kelley Chief People Officer   •       •      –    2025-05-28 4 A $0.00 $0 D/D 22,087 22,087     -
   Deschatelets Pascal Chief Scientific Officer   •       •      –    2025-05-21 4 OE $3.76 $48,053 D/D 12,780 1,160,496     -
   Wheeler Craig A Director   •       •      –    2025-04-17 4 A $0.00 $0 D/D 16,483 16,483     -
   Chopas James George VP/Chief Accounting Officer   •       •      –    2025-03-17 4 S $24.82 $4,543 D/D (183) 47,955 22%     
   Watson David O. General Counsel   •       –      –    2025-03-05 4 S $25.10 $139,789 D/D (5,569) 138,730 26%     
   Watson David O. General Counsel   •       –      –    2025-03-04 4 GA $0.00 $0 I/I 6,667 10,000     -
   Watson David O. General Counsel   •       –      –    2025-03-04 4 GD $0.00 $0 I/I 6,667 0     -
   Delong Mark Jeffrey Chief Business & Strat Officer   •       •      –    2025-02-11 4 S $28.54 $10,360 D/D (363) 83,945 38%     
   Delong Mark Jeffrey Chief Business & Strat Officer   •       •      –    2025-01-29 4 S $29.52 $10,776 D/D (365) 84,308 34%     
   Watson David O. General Counsel   •       •      –    2025-01-29 4 S $29.52 $20,519 D/D (695) 144,299 34%     
   Nicholson Nur Chief Technical Officer   •       •      –    2025-01-29 4 S $29.52 $24,357 D/D (825) 83,664 34%     
   Eisele Jeffrey Chief Development Officer   •       •      –    2025-01-29 4 S $29.52 $8,208 D/D (278) 55,312 34%     
   Deschatelets Pascal Chief Scientific Officer   •       •      –    2025-01-29 4 S $29.52 $24,386 D/D (826) 1,147,716 34%     
   Francois Cedric Chief Executive Officer   •       •      –    2025-01-29 4 S $29.52 $83,375 D/D (2,824) 415,695 34%     
  804 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 33
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us